Male Human Papilloma Virus Infections: How to Prepare for Vaccination Strategies

Abstract

Human papillomavirus (HPV) infections are linked to benign and malignant urogenital conditions, with varying risks associated with different HPV genotypes. Genital warts, mainly caused by low-risk HPV types, have seen a recent surge in incidence, leading to escalating medical costs. While vaccines like Cervarix and Gardasil target females, the exclusion of Gardasil 9 raises questions about gender-neutral vaccination strategies. Studies highlight potential cost savings through male HPV vaccination but note the rising prices of HPV vaccines, particularly Gardasil 9. Recent findings underscore HPV's expansion into nasopharyngeal cancer, urging the introduction of male HPV vaccination programs. However, the increasing vaccine costs raise concerns about accessibility and affordability. Regulatory bodies and healthcare stakeholders must address these challenges to ensure equitable HPV prevention and control measures. Efforts to control vaccine pricing and promote comprehensive immunization strategies are crucial in mitigating the growing burden of HPV-related diseases.